{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:30:03Z","timestamp":1792852203196,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":108,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM201512033"],"award-info":[{"award-number":["SZSM201512033"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Medical Science and Technology Research Project","award":["A2020101"],"award-info":[{"award-number":["A2020101"]}]},{"name":"Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties","award":["SZGSP012"],"award-info":[{"award-number":["SZGSP012"]}]},{"name":"Shenzhen Key Medical Discipline Construction Fund","award":["SZXK034"],"award-info":[{"award-number":["SZXK034"]}]},{"name":"Shenzhen Healthcare Research Project","award":["SZLY2018015"],"award-info":[{"award-number":["SZLY2018015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16289-4","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:32:14Z","timestamp":1781505134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical profiling of AML1::ETO and KIT exon 17 mutation in pediatric AML by high-throughput drug sensitivity"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhilin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guichi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiqiu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huirong","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"16289_CR1","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026. https:\/\/doi.org\/10.1136\/bmj.n2026.","journal-title":"BMJ"},{"key":"16289_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/08880018.2025.2453861","volume":"42","author":"P Iyer","year":"2025","unstructured":"Iyer P. Pediatric AML: state of the art and future directions. Pediatr Hematol Oncol. 2025;42:126\u201345. https:\/\/doi.org\/10.1080\/08880018.2025.2453861.","journal-title":"Pediatr Hematol Oncol"},{"key":"16289_CR3","doi-asserted-by":"publisher","first-page":"e70399","DOI":"10.1096\/fj.202500030R","volume":"39","author":"C Zheng","year":"2025","unstructured":"Zheng C, Zhang C, He Y, Lin S, Zhu Z, Wang H, et al. Cbf\u03b2: a key regulator in skeletal stem cell differentiation, bone development, and disease. FASEB J. 2025;39:e70399. https:\/\/doi.org\/10.1096\/fj.202500030R.","journal-title":"FASEB J"},{"key":"16289_CR4","doi-asserted-by":"publisher","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140. https:\/\/doi.org\/10.1182\/blood.2022016867.","DOI":"10.1182\/blood.2022016867"},{"key":"16289_CR5","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdeO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"key":"16289_CR6","doi-asserted-by":"publisher","first-page":"2406596","DOI":"10.1080\/16078454.2024.2406596","volume":"29","author":"H He","year":"2024","unstructured":"He H, Li J, Li W, Zhao X, Xue T, Liu S, et al. Clinical features and long-term outcomes of pediatric patients with de novo acute myeloid leukemia in China with or without specific gene abnormalities: a cohort study of patients treated with BCH-AML 2005. Hematology. 2024;29:2406596. https:\/\/doi.org\/10.1080\/16078454.2024.2406596.","journal-title":"Hematology"},{"key":"16289_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bjh.16080","volume":"187","author":"K Sakamoto","year":"2019","unstructured":"Sakamoto K, Shiba N, Deguchi T, Kiyokawa N, Hashii Y, Moriya-Saito A, et al. Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: Results from the japanese paediatric leukaemia\/lymphoma study group AML-05 study. Br J Haematol. 2019;187:372\u20136. https:\/\/doi.org\/10.1111\/bjh.16080.","journal-title":"Br J Haematol"},{"key":"16289_CR8","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1111\/ijlh.13338","volume":"43","author":"C Ustun","year":"2021","unstructured":"Ustun C, Morgan EA, Ritz EM, Vestergaard H, Pullarkat S, Kluin PM, et al. Core-binding factor acute myeloid leukemia with inv(16): older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol. 2021;43:e19-25. https:\/\/doi.org\/10.1111\/ijlh.13338.","journal-title":"Int J Lab Hematol"},{"key":"16289_CR9","doi-asserted-by":"publisher","first-page":"783114","DOI":"10.3389\/fonc.2021.783114","volume":"11","author":"M Yang","year":"2021","unstructured":"Yang M, Zhao B, Wang J, Zhang Y, Hu C, Liu L, et al. A predictor combining clinical and genetic factors for AML1-ETO leukemia patients. Front Oncol. 2021;11:783114. https:\/\/doi.org\/10.3389\/fonc.2021.783114.","journal-title":"Front Oncol"},{"key":"16289_CR10","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1016\/j.clml.2021.11.015","volume":"22","author":"NF Shafik","year":"2022","unstructured":"Shafik NF, Ibraheem D, Selim MM, Allam RM, Fathalla LA. The prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2022;22:e363\u201375. https:\/\/doi.org\/10.1016\/j.clml.2021.11.015.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"16289_CR11","doi-asserted-by":"publisher","first-page":"204062072513300","DOI":"10.1177\/20406207251330064","volume":"16","author":"Z Hu","year":"2025","unstructured":"Hu Z, Tang X, Chen F, Li T, Liu Y, Zhou G, et al. Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics. Ther Adv Hematol. 2025;16:20406207251330064. https:\/\/doi.org\/10.1177\/20406207251330064.","journal-title":"Ther Adv Hematol"},{"key":"16289_CR12","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1182\/bloodadvances.2021004735","volume":"5","author":"SE Conneely","year":"2021","unstructured":"Conneely SE, McAtee CL, Gupta R, Lubega J, Scheurer ME, Rau RE. Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia. Blood Adv. 2021;5:4992\u20135001. https:\/\/doi.org\/10.1182\/bloodadvances.2021004735.","journal-title":"Blood Adv"},{"key":"16289_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bjh.17569","volume":"194","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Tsujimoto S, Miyake M, Uchiyama Y, Ikeda J, Yoshitomi M, et al. Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts. Br J Haematol. 2021;194:414\u201322. https:\/\/doi.org\/10.1111\/bjh.17569.","journal-title":"Br J Haematol"},{"key":"16289_CR14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.21037\/tp-20-102","volume":"9","author":"J Fan","year":"2020","unstructured":"Fan J, Gao L, Chen J, Hu S. Influence of KIT mutations on prognosis of pediatric patients with core-binding factor acute myeloid leukemia: A systematic review and meta-analysis. Transl Pediatr. 2020;9:726\u201333. https:\/\/doi.org\/10.21037\/tp-20-102.","journal-title":"Transl Pediatr"},{"key":"16289_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lrr.2018.06.004","volume":"10","author":"P Badr","year":"2018","unstructured":"Badr P, Elsayed GM, Eldin DN, Riad BY, Hamdy N. Detection of KIT mutations in core binding factor acute myeloid leukemia. Leuk Res Rep. 2018;10:20\u20135. https:\/\/doi.org\/10.1016\/j.lrr.2018.06.004.","journal-title":"Leuk Res Rep"},{"key":"16289_CR16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1186\/s12885-023-10965-5","volume":"23","author":"K Qiu","year":"2023","unstructured":"Qiu K, Liao X, Li Y, Huang K, Xu H, Fang J, et al. Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16). BMC Cancer. 2023;23:476. https:\/\/doi.org\/10.1186\/s12885-023-10965-5.","journal-title":"BMC Cancer"},{"key":"16289_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.pedneo.2022.05.020","volume":"64","author":"X Mao","year":"2023","unstructured":"Mao X, Yin R, Liu L, Zhou Y, Yang C, Fang C, et al. Clinical impact of c-KIT and CEBPA mutations in 33 patients with corebinding factor (non-M3) acute myeloid leukemia. Pediatr Neonatol. 2023;64:435\u201341. https:\/\/doi.org\/10.1016\/j.pedneo.2022.05.020.","journal-title":"Pediatr Neonatol"},{"key":"16289_CR18","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1016\/j.clml.2021.09.020","volume":"22","author":"S Srinivasan","year":"2022","unstructured":"Srinivasan S, Kumar S, Vijayasekharan K, Agrawal AK. Prevalence and clinical outcome of FMS-like tyrosine kinase mutations among patients with core binding factor\u2014acute myeloid leukemia: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2022;22:e221\u201332. https:\/\/doi.org\/10.1016\/j.clml.2021.09.020.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"16289_CR19","doi-asserted-by":"publisher","first-page":"1117988","DOI":"10.3389\/fped.2023.1117988","volume":"11","author":"W Lv","year":"2023","unstructured":"Lv W, Chen T, Wang S, Li C, Zhang B, Wang L, et al. Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia. Front Pediatr. 2023;11:1117988. https:\/\/doi.org\/10.3389\/fped.2023.1117988.","journal-title":"Front Pediatr"},{"key":"16289_CR20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1158\/2643-3230.BCD-22-0011","volume":"3","author":"H Wang","year":"2022","unstructured":"Wang H, Chan KYY, Cheng CK, Ng MHL, Lee PY, Cheng FWT, et al. Pharmacogenomic profiling of pediatric acute myeloid leukemia to identify therapeutic vulnerabilities and inform functional precision medicine. Blood Cancer Discov. 2022;3:516\u201335. https:\/\/doi.org\/10.1158\/2643-3230.BCD-22-0011.","journal-title":"Blood Cancer Discov"},{"key":"16289_CR21","doi-asserted-by":"publisher","first-page":"18514","DOI":"10.1038\/s41598-020-75453-3","volume":"10","author":"KM Lappin","year":"2020","unstructured":"Lappin KM, Davis L, Matchett KB, Ge Y, Mills KI, Blayney JK. A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia. Sci Rep. 2020;10:18514. https:\/\/doi.org\/10.1038\/s41598-020-75453-3.","journal-title":"Sci Rep"},{"key":"16289_CR22","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556\u201360. https:\/\/doi.org\/10.1093\/nar\/gkz430.","journal-title":"Nucleic Acids Res"},{"key":"16289_CR23","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1002\/imt2.36","volume":"1","author":"W Shen","year":"2022","unstructured":"Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P, et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta. 2022;1:e36. https:\/\/doi.org\/10.1002\/imt2.36.","journal-title":"iMeta"},{"key":"16289_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3390\/children11050605","volume":"11","author":"J Yang","year":"2024","unstructured":"Yang J, Zhu X, Zhang H, Fu Y, Li Z, Xing Z, et al. Prognostic factors of pediatric acute myeloid leukemia patients with t(8;21) (q22;q22): a single-center retrospective study. Children. 2024;11:605. https:\/\/doi.org\/10.3390\/children11050605.","journal-title":"Children"},{"key":"16289_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/10428194.2017.1361025","volume":"59","author":"X Chen","year":"2018","unstructured":"Chen X, Dou H, Wang X, Huang Y, Lu L, Bin J, et al. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia. Leuk Lymphoma. 2018;59:829\u201336. https:\/\/doi.org\/10.1080\/10428194.2017.1361025.","journal-title":"Leuk Lymphoma"},{"key":"16289_CR26","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/leu.2015.121","volume":"29","author":"M Tokumasu","year":"2015","unstructured":"Tokumasu M, Murata C, Shimada A, Ohki K, Hayashi Y, Saito AM, et al. Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia\/Lymphoma Study Group AML-05 trial. Leukemia. 2015;29:2438\u201341. https:\/\/doi.org\/10.1038\/leu.2015.121.","journal-title":"Leukemia"},{"key":"16289_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hemonc.2016.08.005","volume":"10","author":"H Ayatollahi","year":"2017","unstructured":"Ayatollahi H, Shajiei A, Sadeghian MH, Sheikhi M, Yazdandoust E, Ghazanfarpour M, et al. Prognostic importance of C-KIT mutations in core binding factor acute myeloid leukemia: a systematic review. Hematol Oncol Stem Cell Ther. 2017;10:1\u20137. https:\/\/doi.org\/10.1016\/j.hemonc.2016.08.005.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"16289_CR28","doi-asserted-by":"publisher","first-page":"e35641","DOI":"10.1002\/cncr.35641","volume":"131","author":"C Zhang","year":"2025","unstructured":"Zhang C, Gu R, Wang H, Zhou C, Li Y, Liu Y, et al. Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia. Cancer. 2025;131:e35641. https:\/\/doi.org\/10.1002\/cncr.35641.","journal-title":"Cancer"},{"key":"16289_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12885-023-11784-4","volume":"24","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Pan L, Li J, Feng X, Li C, Zheng M, et al. Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia. BMC Cancer. 2024;24:46. https:\/\/doi.org\/10.1186\/s12885-023-11784-4.","journal-title":"BMC Cancer"},{"key":"16289_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/14737140.2021.1860763","volume":"21","author":"WH Segerink","year":"2021","unstructured":"Segerink WH, de Haas V, Kaspers GJL. Measurable residual disease in pediatric acute myeloid leukemia: a systematic review. Expert Rev Anticancer Ther. 2021;21:451\u20139. https:\/\/doi.org\/10.1080\/14737140.2021.1860763.","journal-title":"Expert Rev Anticancer Ther"},{"key":"16289_CR31","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.3324\/haematol.2021.279134","volume":"107","author":"J Ihlow","year":"2022","unstructured":"Ihlow J, Gross S, Busack L, Fl\u00f6rcken A, Jesse J, Schwarz M, et al. Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy. Haematologica. 2022;107:1773\u201385. https:\/\/doi.org\/10.3324\/haematol.2021.279134.","journal-title":"Haematologica"},{"key":"16289_CR32","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00277-021-04432-z","volume":"100","author":"W Duan","year":"2021","unstructured":"Duan W, Liu X, Zhao X, Jia J, Wang J, Gong L, et al. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. Ann Hematol. 2021;100:1203\u201312. https:\/\/doi.org\/10.1007\/s00277-021-04432-z.","journal-title":"Ann Hematol"},{"key":"16289_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-018-0116-1","volume":"8","author":"Y-Z Qin","year":"2018","unstructured":"Qin Y-Z, Zhu H-H, Jiang Q, Xu L-P, Jiang H, Wang Y, et al. Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). Blood Cancer J. 2018;8:1\u20134. https:\/\/doi.org\/10.1038\/s41408-018-0116-1.","journal-title":"Blood Cancer J"},{"key":"16289_CR34","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-18-1897","volume":"25","author":"K Tarlock","year":"2019","unstructured":"Tarlock K, Alonzo TA, Wang Y-C, Gerbing RB, Ries R, Loken MR, et al. Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia. Clin Cancer Res. 2019;25:5038\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1897.","journal-title":"Clin Cancer Res"},{"key":"16289_CR35","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00277-017-3074-y","volume":"96","author":"S Yui","year":"2017","unstructured":"Yui S, Kurosawa S, Yamaguchi H, Kanamori H, Ueki T, Uoshima N, et al. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. Ann Hematol. 2017;96:1641\u201352. https:\/\/doi.org\/10.1007\/s00277-017-3074-y.","journal-title":"Ann Hematol"},{"key":"16289_CR36","doi-asserted-by":"publisher","first-page":"e30791","DOI":"10.1002\/pbc.30791","volume":"71","author":"S Srinivasan","year":"2024","unstructured":"Srinivasan S, Dhamne C, Patkar N, Chatterjee G, Moulik NR, Chichra A, et al. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1. Pediatr Blood Cancer. 2024;71:e30791. https:\/\/doi.org\/10.1002\/pbc.30791.","journal-title":"Pediatr Blood Cancer"},{"key":"16289_CR37","doi-asserted-by":"publisher","first-page":"6857","DOI":"10.3390\/ijms22136857","volume":"22","author":"S Bruno","year":"2021","unstructured":"Bruno S, Mancini M, De Santis S, Monaldi C, Cavo M, Soverini S. The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities. Int J Mol Sci. 2021;22:6857. https:\/\/doi.org\/10.3390\/ijms22136857.","journal-title":"Int J Mol Sci"},{"key":"16289_CR38","doi-asserted-by":"publisher","first-page":"6888","DOI":"10.3390\/ijms22136888","volume":"22","author":"V Kuek","year":"2021","unstructured":"Kuek V, Hughes AM, Kotecha RS, Cheung LC. Therapeutic targeting of the leukaemia microenvironment. Int J Mol Sci. 2021;22:6888. https:\/\/doi.org\/10.3390\/ijms22136888.","journal-title":"Int J Mol Sci"},{"key":"16289_CR39","doi-asserted-by":"publisher","first-page":"973978","DOI":"10.3389\/fonc.2022.973978","volume":"12","author":"D Magliulo","year":"2022","unstructured":"Magliulo D, Bernardi R. Hypoxic stress and hypoxia-inducible factors in leukemias. Front Oncol. 2022;12:973978. https:\/\/doi.org\/10.3389\/fonc.2022.973978.","journal-title":"Front Oncol"},{"key":"16289_CR40","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1002\/hem3.45","volume":"8","author":"T Velasco-Hernandez","year":"2024","unstructured":"Velasco-Hernandez T, Trincado JL, Vinyoles M, Closa A, Mart\u00ednez-Moreno A, Guti\u00e9rrez-Ag\u00fcera F, et al. Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells. HemaSphere. 2024;8:e45. https:\/\/doi.org\/10.1002\/hem3.45.","journal-title":"HemaSphere"},{"key":"16289_CR41","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1.","journal-title":"Signal Transduct Target Ther"},{"key":"16289_CR42","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.3390\/cancers13164000","volume":"13","author":"E Keewan","year":"2021","unstructured":"Keewan E, Matlawska-Wasowska K. The emerging role of suppressors of cytokine signaling (SOCS) in the development and progression of leukemia. Cancers Basel. 2021;13:4000. https:\/\/doi.org\/10.3390\/cancers13164000.","journal-title":"Cancers Basel"},{"key":"16289_CR43","doi-asserted-by":"publisher","first-page":"e003766","DOI":"10.1136\/jitc-2021-003766","volume":"10","author":"G Leclercq","year":"2022","unstructured":"Leclercq G, Haegel H, Toso A, Zimmermann T, Green L, Steinhoff N, et al. JAK and mTOR inhibitors prevent cytokine release while retaining t cell bispecific antibody in vivo efficacy. J Immunother Cancer. 2022;10:e003766. https:\/\/doi.org\/10.1136\/jitc-2021-003766.","journal-title":"J Immunother Cancer"},{"key":"16289_CR44","doi-asserted-by":"publisher","first-page":"1419951","DOI":"10.3389\/fimmu.2024.1419951","volume":"15","author":"GM Bidgood","year":"2024","unstructured":"Bidgood GM, Keating N, Doggett K, Nicholson SE. SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity. Front Immunol. 2024;15:1419951. https:\/\/doi.org\/10.3389\/fimmu.2024.1419951.","journal-title":"Front Immunol"},{"key":"16289_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1158\/2643-3230.BCD-24-0140","volume":"6","author":"E Tin","year":"2025","unstructured":"Tin E, Rutella S, Khatri I, Na Y, Yan Y, MacLean N, et al. SOCS1 protects acute myeloid leukemia against allogeneic T cell-mediated cytotoxicity. Blood Cancer Discov. 2025;6:217\u201332. https:\/\/doi.org\/10.1158\/2643-3230.BCD-24-0140.","journal-title":"Blood Cancer Discov"},{"key":"16289_CR46","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41420-023-01722-5","volume":"9","author":"P Ayuda-Dur\u00e1n","year":"2023","unstructured":"Ayuda-Dur\u00e1n P, Hermansen JU, Giliberto M, Yin Y, Hanes R, Gordon S, et al. Standardized assays to monitor drug sensitivity in hematologic cancers. Cell Death Discov. 2023;9:435. https:\/\/doi.org\/10.1038\/s41420-023-01722-5.","journal-title":"Cell Death Discov"},{"key":"16289_CR47","doi-asserted-by":"publisher","first-page":"102304","DOI":"10.1016\/j.xcrm.2025.102304","volume":"6","author":"B Haladik","year":"2025","unstructured":"Haladik B, Maurer-Granofszky M, Zoescher P, Jimenez-Heredia R, Frohne A, Segarra-Roca A, et al. Image-based drug screening combined with molecular profiling identifies signatures and drivers of therapy resistance in pediatric AML. Cell Rep Med. 2025;6:102304. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102304.","journal-title":"Cell Rep Med"},{"key":"16289_CR48","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ajh.26700","volume":"97","author":"G Borthakur","year":"2022","unstructured":"Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, et al. Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022;97:1427\u201334. https:\/\/doi.org\/10.1002\/ajh.26700.","journal-title":"Am J Hematol"},{"key":"16289_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3324\/haematol.2018.191841","volume":"104","author":"N Niktoreh","year":"2019","unstructured":"Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin J-P, et al. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-M\u00fcnster study group. Haematologica. 2019;104:120\u20137. https:\/\/doi.org\/10.3324\/haematol.2018.191841.","journal-title":"Haematologica"},{"key":"16289_CR50","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41375-025-02700-9","volume":"39","author":"J Ronnacker","year":"2025","unstructured":"Ronnacker J, Muller PJ, Mikesch J-H, Zukunft S, Weinbergerov\u00e1 B, \u0160r\u00e1mek J, et al. Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis. Leukemia. 2025;39:2174\u201380. https:\/\/doi.org\/10.1038\/s41375-025-02700-9.","journal-title":"Leukemia"},{"key":"16289_CR51","doi-asserted-by":"publisher","first-page":"107467","DOI":"10.1016\/j.leukres.2024.107467","volume":"139","author":"G Bourne","year":"2024","unstructured":"Bourne G, Diebold K, Espinoza-Gutarra M, Al-Kadhimi Z, Bachiashvili K, Rangaraju S, et al. Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia. Leuk Res. 2024;139:107467. https:\/\/doi.org\/10.1016\/j.leukres.2024.107467.","journal-title":"Leuk Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16289-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16289-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16289-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:08:36Z","timestamp":1790831316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16289-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16289"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16289-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of Shenzhen Children\u2019s Hospital (Approval No. 202111202) and conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1159"}}